Business in brief
Federal regulators have put off their approval decision on an anti-alcoholism drug because the developer, Alkermes Inc., changed its application, the Cambridge company said. Shares fell $1.67, or 8.9 percent, to $17. Vivitrex is a monthly injectable version of naltrexone. It was scheduled for a Sept. 30 approval decision by the Food and Drug Administration, but the company said the ... (Full article: 752 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
